[Translation] A single-dose, randomized, open-label, two-dose, two-period, two-sequence, self-crossover, fasting/fed bioequivalence study of brepazole tablets in healthy Chinese subjects
主要研究目的:考察中国健康受试者在空腹/餐后条件下单剂量口服山东华铂凯盛生物科技有限公司提供的受试制剂布瑞哌唑片(规格:2mg)与 Otsuka Pharmaceutical Co., Ltd. 生产的参比制剂布瑞哌唑片(商品名:REXULTI®;规格:2mg)后的体内药代动力学特征,评价两制剂的生物等效性。次要研究目的:观察受试制剂和参比制剂在健康受试者中的安全性。
[Translation] The main purpose of the study is to investigate the in vivo pharmacokinetic characteristics of the test preparation brepirazole tablets (specification: 2 mg) provided by Shandong Huabo Kaisheng Biotechnology Co., Ltd. and the reference preparation brepirazole tablets (trade name: REXULTI®; specification: 2 mg) produced by Otsuka Pharmaceutical Co., Ltd. in healthy Chinese subjects after a single oral dose under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. The secondary purpose of the study is to observe the safety of the test preparation and the reference preparation in healthy subjects.